Date: 2013-05-22
Type of information: Development agreement
Compound: antibiotics
Company: GSK (UK) Department of Health and Human Services (HHS) (USA)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism:
Disease:
Details: * On May 22, 2013, GSK and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), have agreed to collaborate to support the development of several antibiotics to fight antibiotic resistance and bioterrorism.
This public-private agreement marks the first time that HHS has taken a “portfolio approach” to funding drug development with a private sector company. This unique collaboration provides flexibility to move funding around GSK’s antibacterial portfolio, rather than focusing on just one drug candidate and allow medicines to be studied for the potential treatment of both conventional and biothreat pathogens.
The work under this agreement will be governed by a BARDA-GSK joint oversight committee that will monitor progress, make decisions on the allocation of funds and decide on the addition or removal of drug candidates from the portfolio.
Financial terms: Under the terms of the agreement, HHS will provide $40 million for the initial 18-month agreement and up to a total of $200 million if the agreement is renewed over five years.
Latest news:
